Antimalarial Drug Quality in the Most Severely Malarious Parts of Africa – A Six Country Study

Roger Bate1,2, Philip Coticelli1*, Richard Tren1, Amir Attaran3

1 Africa Fighting Malaria, Washington, D. C., United States of America, 2 American Enterprise Institute, Washington, D. C., United States of America, 3 Institute of Population Health & Faculties of Law and Medicine, University of Ottawa, Ottawa, Canada

Abstract

A range of antimalarial drugs were procured from private pharmacies in urban and peri-urban areas in the major cities of six African countries, situated in the part of that continent and the world that is most highly endemic for malaria. Semi-quantitative thin-layer chromatography (TLC) and dissolution testing were used to measure active pharmaceutical ingredient content against internationally acceptable standards. 35% of all samples tested failed either or both tests, and were substandard. Further, 33% of treatments collected were artemisinin monotherapies, most of which (78%) were manufactured in disobservance of an appeal by the World Health Organisation (WHO) to withdraw these clinically inappropriate medicines from the market. The high persistence of substandard drugs and clinically inappropriate artemisinin monotherapies in the private sector risks patient safety and, through drug resistance, places the future of malaria treatment at risk globally.

Citation: Bate R, Coticelli P, Tren R, Attaran A (2008) Antimalarial Drug Quality in the Most Severely Malarious Parts of Africa – A Six Country Study. PLoS ONE 3(5): e2132. doi:10.1371/journal.pone.0002132

Editor: Philip Awadalla, University of Montreal, Canada

Received February 14, 2008; Accepted April 8, 2008; Published May 7, 2008

Copyright: © 2008 Bate et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Funding for this study was provided in full by Africa Fighting Malaria, drawing on a general budgetary support grant made by the Ohrstrom Foundation. The authors’ work was entirely independent of the Ohrstrom Foundation.

Competing Interests: In the past five years Roger Bate and Amir Attaran received travel grants from pharmaceutical company Novartis, and Amir Attaran received a consulting fee. No funding was received in respect of this research. Amir Attaran also received consulting and/or travel fees from the WHO and World Bank, and is a member of the WHO Global Malaria Programme Technical and Research Advisory Committee. No member of the study team received any funds from a competing interest for the performance of this study.

* E-mail: pcoticelli@fightingmalaria.org

Introduction

Malaria surged in sub-Saharan Africa in the 1990s, due in part to increased resistance to chloroquine and sulfadoxine-pyrimethamine (SP).[1] Exposure to substandard antimalarial drugs likely exacerbated this trend.[2,3,4] Pressure from malaria scientists prompted wholesale adoption of artemisinin-based combination therapies (ACTs) by endemic country governments and donors.[5] In January 2006, the WHO issued new treatment guidelines for the first time in 20 years recommending ACTs for the treatment of uncomplicated malaria. The WHO further called to end the production and marketing of artemisinin monotherapies in order to protect these formulations against parasitic resistance. According to the WHO’s antimalarial drug quality database, every national treatment policy in sub-Saharan Africa except Swaziland and Cape Verde now recommends treating uncomplicated malaria with ACTs.

These well-intentioned changes might remain unrealized and vulnerable. Substandard ACTs, and “legitimate” artemisinin monotherapies, are unparalleled threats driving clinical failure of malaria treatment.[6,7,8] Especially in Sub-Saharan Africa, governments lack the ability through customs and policing to stop these medicines entering the private market, where many (oftentimes most) persons buy their treatment.[9,10] Unless these medicines are of a consistently high quality, the great strides made in recent years to transition from chloroquine and SP to ACTs could be imperiled by drug resistance. This study is the first to sample the quality of medicines throughout the geographic band of hyper- and holoendemic P. falciparum malaria which stretches unbroken from West, to Central, to East Africa—the world’s worst.[11]

Results

195 treatment packs were tested, producing 210 sample results. The difference between tests and results is explained in that co-packaged, but not co-formulated ACTs, such as artesunate and amodiaquine were tested as individual monotherapies.

Overall 35% (73/210) of tested samples were substandard and failed either TLC or dissolution tests (See Table 1). Of the specific pharmaceutical types, failure by TLC, dissolution or both, occurred in 38% of SP, 48% of amodiaquine, 24% of mefloquine, 31% of artesunate, 27% of artemether, 55% of dihydroartemisinin and 19% of artemether-lumefantrine fixed-dose combinations.

Artemisinin monotherapy, which the WHO rejects as inherently substandard treatment even when its dosage is correct, remains common in Africa. 33% (64/195) of all treatment packs tested were artesunate monotherapies, and 42% (27/64) failed either TLC or dissolution tests. 78% (50/64) were manufactured after the WHO’s January 2006 appeal to halt monotherapy production. A further sign that certain manufacturers of artemisinin monotherapies do not take clinical efficacy seriously was the tremendous heterogeneity in expiry dates: 10 listed an expiration date of two years, while most (42/64) listed three years. Five listed an expiration date of four years, and seven lacked either a manufacture date or both a manufacture date and expiration date. This is not uncommon for private sector supplies.
In this study were forwarded to the WHO.

date. Names of the offending artemisinin monotherapy producers in this study were forwarded to the WHO.

The authors did not attempt a forensic examination of trademarks or product designs to differentiate between products that were merely substandard and those which were deliberately counterfeited, as neither is clinically suitable. However, there was an apparent trend in that failing products more often originated or were claimed to originate from poorer parts of the world with weaker regulatory systems: failure rates were 48% (30/63) for Africa, 32% (29/90) for Asia and 24% (12/50) for Europe (See Table 2). Only four US-manufactured samples were tested; none failed.

Discussion

This study sheds light on the availability and relative quality of private sector antimalarials in Africa’s private sector. In countries situated in the world’s most intense region of holoendemic and hyperendemic *P. falciparum* malaria, where the difference between a proper and a bogus medicine cannot be surpassed, various substandard therapies and clinically inappropriate monotherapies remain widely available, with between a quarter and over half of products sold in urban and peri-urban pharmacies failing basic quality testing. We do not quantitatively estimate the public health impact of this crisis, but it must be staggering.

The WHO has taken diplomatic steps to fight this problem. It coordinates a passive reporting system for substandard medicines, and can be run in an ordinary air-conditioned room. There are no special training, and can be run in an ordinary air-conditioned room. The capacity for basic drug quality tests to strengthen post-market surveillance, it risks to expand the supply of the substandard and inappropriate treatments found in this study, which would be disastrous in clinical and drug resistance terms both.[13]

Further, this study demonstrates that at the local level, the capacity for basic drug quality tests to strengthen post-market surveillance can be deployed with relative ease. A Minilab equivalent technology costs about $4,000, requires modest training, and can be run in an ordinary air-conditioned room.

The Global Fund, for example, finances the purchase of medicines whose quality is not approved by the WHO’s prequalification scheme or any developed country’s regulatory authority—known as “Option C” medicines. According to an internal report published by the Wall Street Journal, the World Bank recently discovered in an audit that malaria medicines it purchased in India from a local manufacturer were clinically substandard.

These incidents argue strongly for a rule against purchasing locally-manufactured medicines, except where those medicines have received regulatory approval from a developed country or the WHO’s prequalification scheme. The WHO’s current practice, which regards a medicine as good enough if it has applied for prequalification, but not necessarily passed the WHO quality standards and received prequalification, is an unprincipled distortion of the rules. Similarly stringent rules must inure to the proposed $1.9 billion Affordable Medicines Facility for malaria, which intends to provide clinically effective ACTs at retail outlets where they are needed. Unless this initiative employs standards higher than the current Global Fund and World Bank ones and strengthens post-market surveillance, it risks to expand the supply of the substandard and inappropriate treatments found in this study, which would be disastrous in clinical and drug resistance terms both.[13]

### Table 1. Testing results by formulation and country purchased for TLC and dissolution

|                | Ghana | Kenya | Nigeria | Rwanda | Tanzania | Uganda | Total |
|----------------|-------|-------|---------|--------|----------|---------|-------|
| Sulphadoxine-pyrimethamine | 50% (3/6) | 38% (6/16) | 50% (1/2) | 50% (3/6) | 27% (3/11) | 33% (3/9) | 38% (19/50) |
| Amodiaquine     | 33% (2/6) | 50% (4/8) | 25% (1/4) | -       | 100% (2/2) | 56% (5/9) | 48% (14/29) |
| Mefloquine      | 0% (0/1)  | -     | 50% (1/2) | -       | 0% (0/3)  | 27% (3/11) | 24% (4/17)  |
| Artesunate      | 38% (3/8) | 0% (0/4) | 33% (2/6) | -       | 31 (4/13) | 33% (6/18) | 31% (15/49) |
| Artemether      | 0% (0/3)  | 100% (1/1) | -       | -       | -       | 29% (2/7)  | 27% (3/11)  |
| Dihydro-artemisinin | 40% (2/5) | 56% (5/9) | 100% (1/1) | -       | 50% (2/4) | 67% (2/3)  | 55% (12/22) |
| Artemether-lumefantrine fixed-dose combination | 38% (3/8) | 0% (0/4) | 14% (1/7) | 0% (0/3) | 0% (0/1) | 22% (2/9)  | 19% (6/32)  |
| **Total**       | **35% (13/37)** | **38% (16/42)** | **32% (7/22)** | **33% (3/9)** | **32% (11/34)** | **35% (23/66)** | **35% (73/210)** |

1 Percentages are supported by (total that failed either dissolution or TLC/total treatments tested)

### Table 2. Testing results by region of manufacture

| Region of manufacture | Total Samples Failing TLC or Dissolution | Total Samples Tested | Percent Failed |
|-----------------------|-----------------------------------------|---------------------|----------------|
| Africa                | 30                                      | 63                  | 48%            |
| Asia                  | 29                                      | 90                  | 32%            |
| Europe                | 12                                      | 50                  | 24%            |
| US                    | 0                                       | 4                   | 0%             |

Manufacturer information not available for 3 tested samples; (doi:10.1371/journal.pone.0002132.t0002)
The marginal cost to test 10 samples out of 10,000 (for a sampling ratio of 0.1%) is about $2, and can be completed in under an hour. Training programs for district level malaria officers and regulatory officials in Southeast Asia could be replicated in sub-Saharan Africa. Such simple and cheap technology should be distributed more widely, to the ministry of health, police, customs services and non-governmental organizations. A decentralized effort of this kind, with drug quality watchdogs at several layers of government and in civil society, could be effectively tried in a country for only tens of thousands of dollars.

Materials and Methods

A simple sampling protocol was developed in line with similar studies. Antimalarial drugs were obtained by local nationals from randomly selected private pharmacies in the major cities of six African countries within the high endemicity band. Study agents posed as customers were asked to purchase a sample lot of antimalarial tablet formulations available, namely: SP, amodiaquine, mefloquine, artemisinin monotherapies and any ACTs. Agents were instructed not to purchase chloroquine. Treatment packs were maintained either in the manufacturer’s original packaging or loose, and stored at ambient temperature until testing. Tests were completed within 40 days of sample collection.

The Global Pharma Health Fund e.V. Minilab® was used to run semi-quantitative thin-layer chromatography (TLC) and dissolution tests on each sample to determine the presence and relative concentration of active ingredients. Each test was run in duplicate, with the generous assumption that the result more consistent with the reference was recorded. The Minilab® protocols award products a “pass” if they have 80% or more of the labeled active ingredient(s) (note there is no upper-bound limit). For fixed-dose combinations and SP, “pass” was awarded only if both active ingredients met this standard.

Acknowledgments

The authors would like to thank Kimberly Hess for her analysis of study data, as well as Carlos Odora, Franklin Cudjoe, Thompson Ayodele, Greg Starbird and Aime Mutembe for their invaluable help in the collection of drugs studied.

Author Contributions

Conceived and designed the experiments: RB. Performed the experiments: AA RT PC RB. Analyzed the data: RT PC RB. Wrote the paper: AA RT PC RB.

References

1. Gomes M, Wayling S, Pang L (1998) Interventions to improve the use of antimalarials in south-east Asia: an overview. Bull World Health Organ 76(1): 9–18.
2. Miniz OMS, Moshi MJ, Hipolite D, Massele AV, Tomson G, et al. (2003) Evaluation of the quality of amodiaquine and sulphadoxine/pyrimethamine tablets sold by private wholesale pharmacies in Dar Es Salaam Tanzania. Journal of Clinical Pharmacy and Therapeutics 28: 117–122.
3. Amin AA, Snow RW, Kokwaro GO (2005) The quality of sulphadoxine-pyrimethamine and amodiaquine products in the Kenyan retail sector. Journal of Clinical Pharmacy and Therapeutics 30: 559–565.
4. Basco LK (2004) Molecular epidemiology of malaria in Cameroon. XIX. Quality of antimalarial drug used for self-medication. Am J Trop Med Hyg 70(3): 245–250.
5. Attaran A, Barnes KI, Curtis C, D’Alessandro U, Fanello CI, et al. (2004) WHO, the Global Fund and medical malpractice in malaria treatment. The Lancet 363(9404): 237–240.
6. Dondorp AM, Newton PN, Mayxay M, Van Damme W, Smithuis FM, et al. (2004) Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health 9(12): 1241–6.
7. Hall KA, Newton PN, Green MD, De Veij M, Vandenabeele P, et al. (2006) Characterization of counterfeit artesunate antimalarial tablets from southeast Asia. Am J Trop Med Hyg 75(3): 404–411.
8. Newton PN, McGready R, Fernandez F, Green MD, Sunjio M, et al. (2006) Manslaughter by Fake Artesunate in Asia—Will Africa Be Next? PLoS Med 3(6): e197 doi:10.1371/journal.pmed.0030197.
9. Snow RW, Peshu N, Forster D, Mwenza H, Marsh K (1992) The role of shops in the treatment and prevention of childhood malaria on the coast of Kenya. Trans R Soc Trop Med Hyg 86(3): 237–239.
10. Goodman C, Briger B, Uwin A, Mills A, Meek S, et al. (2007) Medicine Sellers and Malaria Treatment in Sub-Saharan Africa: What Do They Do and How Can Their Practice Be Improved? Am J Trop Med Hyg 77(6): 203–218.
11. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI (2005) The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434(7030): 214–217.
12. Lon CT, Tsuyuoka R, Phanouvong S, Nivanna N, Socheat D, et al. (2006) Counterfeit and substandard antimalarial drugs in Cambodia. Transactions of the Royal Society of Tropical Medicine and Hygiene 100: 1019–1024.
13. Green MD (2006) Antimalarial drug resistance and the importance of drug quality monitoring. J Postgrad Med 52(4): 208–210.
14. Vijayakadga S, Cholpol S, Sitthimongkol S, Pawaphutanan A, Pinyoratanachat A, et al. (2006) Strengthening of national capacity in implementation of antimalarial drug quality assurance in Thailand. Southeast Asian J Trop Med Public Health 37(3): 5–10.